What is Leerink Partnrs’ Forecast for Zura Bio Q1 Earnings?

Zura Bio Limited (NASDAQ:ZURA) – Equities research analysts at Leerink Partnrs increased their Q1 2025 EPS estimates for shares of Zura Bio in a report issued on Tuesday, March 25th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will post earnings of ($0.13) per share for the quarter, up from their prior forecast of ($0.15). The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share. Leerink Partnrs also issued estimates for Zura Bio’s Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.53) EPS and FY2026 earnings at ($0.48) EPS.

ZURA has been the topic of a number of other reports. Guggenheim reissued a “buy” rating and set a $15.00 price objective on shares of Zura Bio in a report on Wednesday. Oppenheimer restated an “outperform” rating and issued a $19.00 price objective (down from $20.00) on shares of Zura Bio in a report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. HC Wainwright reiterated a “neutral” rating and issued a $5.00 price objective on shares of Zura Bio in a report on Tuesday, December 24th. Finally, Chardan Capital lowered their price objective on Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $15.00.

Zura Bio Stock Up 1.5 %

Shares of ZURA stock opened at $1.36 on Friday. The business has a 50-day moving average price of $1.47 and a two-hundred day moving average price of $2.75. Zura Bio has a 12-month low of $1.07 and a 12-month high of $6.35.

Zura Bio (NASDAQ:ZURA) last announced its earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.09. The company had revenue of $0.00 million during the quarter.

Institutional Investors Weigh In On Zura Bio

Several institutional investors and hedge funds have recently bought and sold shares of ZURA. SG Americas Securities LLC increased its stake in shares of Zura Bio by 51.6% during the fourth quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock valued at $58,000 after buying an additional 7,828 shares during the period. Wells Fargo & Company MN boosted its holdings in Zura Bio by 68.6% in the fourth quarter. Wells Fargo & Company MN now owns 23,053 shares of the company’s stock valued at $58,000 after acquiring an additional 9,379 shares in the last quarter. Bank of America Corp DE increased its position in Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after purchasing an additional 9,966 shares during the period. Rhumbline Advisers increased its position in Zura Bio by 37.3% during the 4th quarter. Rhumbline Advisers now owns 37,657 shares of the company’s stock valued at $94,000 after purchasing an additional 10,231 shares during the period. Finally, American Century Companies Inc. bought a new position in Zura Bio in the 4th quarter worth $27,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.